Mpox outbreak: Canada's response and ongoing surveillance

Canada’s monitoring and surveillance efforts

In response to the global outbreak, PHAC has intensified its surveillance efforts, particularly in areas where the virus has shown signs of spreading. Since July 2022, Canada has been monitoring the presence of mpox in the country through wastewater surveillance, a method that allows for early detection of viral particles. This approach has been crucial in identifying the presence of Clade II mpox, the strain that has been detected in Canada.

PHAC’s surveillance capabilities include testing for both Clade I and Clade II of the virus. While Clade I, which is primarily found in Africa, has not been detected in Canada, Clade II has been circulating in the country since 2022. PHAC has indicated that, at this time, the risk posed by Clade I mpox to Canadians is minimal. However, the ongoing presence of Clade II in certain regions, particularly in Toronto, has led to an increase in cases, prompting further vigilance.

Vaccination and public health guidance

To combat the spread of mpox, Canada has secured a sufficient supply of vaccines, ensuring that provincial and territorial health programs are well-equipped to prevent and control outbreaks. In May 2024, the National Advisory Committee on Immunization (NACI) updated its guidance, recommending a two-dose vaccination series for adults who are at high risk of exposure to the virus. This vaccine is designed to protect against both Clade I and Clade II strains of mpox.

Despite the availability of the vaccine, PHAC currently does not recommend vaccination for the general public. The focus remains on those at highest risk, particularly individuals who may be exposed in regions where the virus is more prevalent. PHAC continues to work closely with Global Affairs Canada and other partners to update risk assessments, public health guidance, and travel advice as the situation evolves.

Travel precautions and global concerns

Given the ongoing outbreak in the Democratic Republic of Congo (DRC) and neighboring countries, PHAC has maintained a Level 2 travel notice for the region since April. This advisory encourages travelers to take enhanced health precautions, particularly if they plan to attend gatherings or events where close and prolonged contact is likely, such as during sexual activity. The travel notice serves as a critical reminder for Canadians to be vigilant when traveling to areas affected by the virus.

While the global spread of mpox remains a concern, Canada’s proactive measures, including targeted vaccination campaigns and robust surveillance systems, have been instrumental in mitigating the risk of a widespread outbreak within the country. PHAC’s continued efforts to monitor the virus and update public health guidance ensure that Canadians are well-informed and protected against the potential dangers posed by mpox.

The mpox outbreak, while serious on a global scale, has been met with a comprehensive response from Canadian health authorities. Through diligent monitoring, targeted vaccination, and clear public health communication, Canada has effectively managed the risk associated with the virus. As the situation continues to evolve, PHAC remains committed to safeguarding the health of Canadians, adapting strategies as needed to respond to this global health challenge.

source: Global News CA